ClinicalTrials.gg
CompletedNCT03343145Updated Dec 28, 2020

A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients

A Phase 3 interventional study of Leucostim 5µg/kg/day and Neupogen 5µg/kg/day in Breast Cancer, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Indonesia. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-12-28.

Sponsored by Dong-A ST Co., Ltd. · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2017, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Breast Neoplasms with a site in Indonesia — 9 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Indonesia.

Enrollment
10th of 28
143 · median 74
Started
2017
with 1 other
Phase 3
7 of 34
none open now
Registered
10th of 34
by date

Among the 34 studies in Breast Neoplasms with a site in Indonesia, this one is the 10th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 10th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 34 studies in Breast Neoplasms with a site in Indonesia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Breast Neoplasms with a site in Indonesia, or all of them as a file.
02

Study summary

A study to compare the efficacy, safety and immunogenicity of Leucostim® to those of Neupogen® in patients with breast cancer intended to be treated with TAC regimen as a myelosuppressive chemotherapy.

Read the detailed description

TAC regimen (docetaxel, doxorubicin and cyclophosphamide) is recommended for the adjuvant treatment of breast cancer patients. The TAC regimen is known to lead to significant hematological toxicity and induces febrile neutropenia with a rate > 20%. The use of primary G-CSF prophylaxis with the TAC regimen is recommended by guidelines. e.g., by the European Organisation for Research and Treatment of Cancer as well as by the guideline on myeloid growth factors of the National Comprehensive Cancer Network.6,7 This study is to compare the efficacy, safety and immunogenicity of Leucostim® to those of Neupogen® in patients with breast cancer intended to be treated with TAC regimen as a myelosuppressive chemotherapy.

03

Conditions studied

  • Breast Cancer

Keywords

  • Neutropenia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to provide a written
  2. Men or women ≥ 18 and ≤ 70 years of age
  3. or cytologically confirmed breast cancer (Stage II to Stage IV)
  4. Be scheduled to receive TAC regimen as therapy
  5. Subjects who meet the conditions at screening test as follows;

    • (ANC) ≥ 1,500/mm3
    • Count ≥ 100,000/mm3
    • Performance Status : 0\~2
  6. Adequate renal function (Creatinine ≤ 1.5 x at screening test)
  7. Adequate hepatic function at screening test (Total //ALT ≤ 1.5 x ULN, ALP ≤ 2.5 x ULN at screening test)

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy experiences
  2. Prior bone marrow or stem cell transplantation
  3. History of treatment with hematopoietic growth factors (e.g. G-CSF, peg-G-CSF, erythropoietin)
  4. History of prior other than breast cancer or surgically cured malignancies within 5 years of date
  5. Participation in any other clinical study within 4 weeks of informed consent date or planning to simultaneously participate in another clinical study
  6. Currently receiving radiation therapy or having completed radiation therapy within 4 weeks of informed consent date
  7. Active infection which may require systemic antimicrobial or antiviral therapy during the study (e.g. ≥ 12,000/mm3 or Body Temperature > 38.2 degrees C (100.8 degrees F))
  8. History of systemic antibiotic use within 72 hours prior to chemotherapy
  9. History of to the product, components or similar products
  10. positive
  11. Pregnant or lactating women, or women of who are not willing to follow a reliable and effective measure during the course of the study and for at least one month after the completion of the study
  12. Any other cases that is considered by the investigator as an exclusion
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    Test Drug Group

    Leucostim 5µg/kg/day

    Biological: Leucostim 5µg/kg/day

  • Active comparator
    Reference Drug Group

    Neupogen 5µg/kg/day

    Biological: Neupogen 5µg/kg/day

Interventions

  • BiologicalLeucostim 5µg/kg/day

    5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir

  • BiologicalNeupogen 5µg/kg/day

    Drug page: Filgrastim

    5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir

06

What researchers measure

Primary outcomes

  1. Mean duration of Grade 4 Neutropenia (i.e. ANC < 500/mm3) in Cycle 1

    Time frame: Maximum of 14 Days

Secondary outcomes

  1. Depth of ANC nadir after chemotherapy in Cycle 1

    Time frame: Maximum of 14 Days

  2. Time to ANC recovery in Cycle 1

    Time frame: Maximum of 14 Days

  3. Incidence of febrile neutropenia in Cycle 1;

    Time frame: Maximum of 14 Days

Other outcomes

  1. Anti-rhG-CSF antibody formation

    Time frame: 180±14d

07

Study locations

1 site
  • RSUP Dr. Hasan Sadikin
    Bandung, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jan 2019, 24 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 24 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2017
First posted
Nov 17, 2017
StartActual
Jan 12, 2017
Primary completionActual
Jan 28, 2019
CompletionActual
Jul 29, 2019
Last update
Dec 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03343145
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Jan 12, 2017
Primary completion
Jan 28, 2019
Completion
Jul 29, 2019
Last update
Dec 28, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion